Boral Capital sets $22 target on Scilex shares, rating Buy
In addition to ZTlido, Scilex's portfolio features Elyxyb, an oral celecoxib solution for migraines, which may also find broader use for acute pain such as tension headaches. Another product ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Scilex seeks FDA nod for ELYXYB in acute pain management
PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a pharmaceutical company with a current market capitalization of $82.28 million and impressive revenue growth of 22% over the last twelve ...